These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 1980775)

  • 1. [Treatment of therapy-resistant acromegaly using Sandostatin].
    von Werder K; Mehltretter G; Müller OA
    Z Gastroenterol; 1990 Sep; 28 Suppl 2():29-31. PubMed ID: 1980775
    [No Abstract]   [Full Text] [Related]  

  • 2. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
    Laczi F; Magony S; Julesz J
    Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective treatment of recurrent acromegaly with a long-active somatostatin analogue (sandostatin).
    Miranda R; Zárate A; Ruíz Velasco G
    Arch Invest Med (Mex); 1988; 19(4):445-8. PubMed ID: 3245759
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly.
    Ma P; Wang Y; van der Hoek J; Nedelman J; Schran H; Tran LL; Lamberts SW
    Clin Pharmacol Ther; 2005 Jul; 78(1):69-80. PubMed ID: 16003295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for octreotide subcutaneously in the treatment of acromegaly.
    Liuzzi A; Oppizzi G
    J Endocrinol; 1997 Oct; 155 Suppl 1():S61-5. PubMed ID: 9389999
    [No Abstract]   [Full Text] [Related]  

  • 6. [Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests].
    Schmidt K; Althoff PH; Harris A; Hofmeister-Wagner W; Schifferdecker E; Schöffling K
    Med Klin (Munich); 1990 Dec; 85(12):700-6. PubMed ID: 2128367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
    Turner HE; Thornton-Jones VA; Wass JA
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Experience in treating acromegalic patients with long-acting octreotide].
    Szücs N; Mészáros J; Czirják S; Mondok A; Varga I; Gláz E
    Orv Hetil; 2002 May; 143(19 Suppl):1066-70. PubMed ID: 12063862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Behavior of the pituitary-thyroid axis in acromegalic subjects during prolonged intermittent and pulsatile treatment with octreotide].
    Cuttica CM; Fazzuoli L; Cariola G; Carraro A; Porcella E; Giusti M; Giordano G
    Recenti Prog Med; 1994 Jan; 85(1):7-12. PubMed ID: 8184183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of acromegaly with octreotide: effectiveness and tolerability of its pulsatile administration by portable pump.
    Giusti M; Cuttica CM; Cariola G; Valenti S; Sessarego P; Giordano G
    Recenti Prog Med; 1995 May; 86(5):189-94. PubMed ID: 7604174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment of acromegaly with a long-acting analogue of somatostatin, octreotide.
    Page MD; Millward ME; Taylor A; Preece M; Hourihan M; Hall R; Scanlon MF
    Q J Med; 1990 Feb; 74(274):189-201. PubMed ID: 2111918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of the efficacy of Octreotide LAR in the treatment of acromegaly--a yearly observation].
    Bałdys-Waligórska A; Gołkowski F; Krzentowska A; Sokołowski G; Hubalewska-Dydejczyk A
    Przegl Lek; 2009; 66(5):218-21. PubMed ID: 19739577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoatrophy induced by subcutaneous administration of octreotide in the treatment of acromegaly.
    Atmaca A; Erbas T
    Exp Clin Endocrinol Diabetes; 2005 Jun; 113(6):340-3. PubMed ID: 15977102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS; Musolino NR; Salgado LR; Bronstein MD
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly.
    Gilbert JA; Miell JP; Chambers SM; McGregor AM; Aylwin SJ
    Clin Endocrinol (Oxf); 2005 Jun; 62(6):742-7. PubMed ID: 15943838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly.
    Plöckinger U; Dienemann D; Quabbe HJ
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1658-62. PubMed ID: 2229321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. All aboard for octreotide.
    Lancet; 1990 Oct; 336(8720):909-11. PubMed ID: 1976932
    [No Abstract]   [Full Text] [Related]  

  • 18. Octreotide.
    Kendall-Taylor P; Chatterjee S; White MC; Harris MM; Davidson K; Besser GM; Wass JA
    Lancet; 1989 Oct; 2(8667):859-60. PubMed ID: 2571774
    [No Abstract]   [Full Text] [Related]  

  • 19. Sonography of gallbladder abnormalities in acromegaly patients following octreotide and ursodiol therapy: incidence and time course.
    Avila NA; Shawker TH; Roach P; Bradford MH; Skarulis MC; Eastman R
    J Clin Ultrasound; 1998; 26(6):289-94. PubMed ID: 9641388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of long term octreotide on gall stone formation and gall bladder function.
    Bigg-Wither GW; Ho KK; Grunstein RR; Sullivan CE; Doust BD
    BMJ; 1992 Jun; 304(6842):1611-2. PubMed ID: 1628089
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.